ESSA Pharma Inc EPIX.OQ EPIX.O is expected to report results on August 4 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for ESSA Pharma Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 65.2% in the last three months.
Wall Street's median 12-month price target for ESSA Pharma Inc is $1.70, below its last closing price of $1.71.
This summary was machine generated May 9 at 15:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)